Assistance Options for Your Eligible Patients
Several options are available to help eligible patients with the out-of-pocket (OOP) costs of TECENTRIQ.
Find out if your patients could be eligible using the Patient Assistance Tool.
Several options are available to help eligible patients with the out-of-pocket (OOP) costs of TECENTRIQ.
Find out if your patients could be eligible using the Patient Assistance Tool.
Is your patient insured?
Does the patient's insurance cover his or her Genentech medicine?
Has your patient already been referred to the Genentech Oncology Co-pay Assistance Program and is either ineligible or no longer receiving assistance?
Has your patient already been referred to an independent co-pay assistance foundation and is either ineligible or no longer receiving assistance?
Is the patient 18 years of age or older?
Your Patient Might Qualify for a Referral to the Genentech Oncology Co-pay Assistance Program
If eligible commercially insured patients need assistance with their out-of-pocket costs, TECENTRIQ Access Solutions can refer them to the Genentech Oncology Co-pay Assistance Program.*
*Eligibility criteria apply. Not valid for patients using federal or state government programs to pay for their medications and or administration of their Genentech medication. Patient must be taking the Genentech medication for an FDA-approved indication. See full Terms and Conditions at CopayAssistanceNow.com.
Your Patient Might Qualify for a Referral to an Independent Co-pay Assistance Foundation
For eligible patients with commercial or public health insurance, TECENTRIQ Access Solutions offers referrals to independent co-pay assistance foundations.*
*Advise your patient that these organizations are independent of Genentech and may require the patient to provide personal or financial information directly to the organization to enroll in their respective programs. Genentech cannot share any information the patient has provided to us.
Independent co-pay assistance foundations have their own rules for eligibility. We have no involvement or influence in independent foundation decision-making or eligibility criteria and do not know if a foundation will be able to help your patient. We can only refer your patient to a foundation that supports their disease state. This information is provided as a resource for you. We do not endorse or show preference for any particular foundation. The foundations in this list may not be the only ones that might be able to help your patient.
Your Patient Might Qualify for a Referral to the Genentech Patient Foundation
The Genentech Patient Foundation provides free Genentech medicine to people who don't have insurance coverage or who have financial concerns and meet eligibility criteria.*
*To be eligible for free Genentech medicine from the Genentech Patient Foundation, insured patients who have coverage for their medicine should try to pursue other forms of financial assistance, if available, and meet certain income requirements. Uninsured patients and insured patients without coverage for their medicine must meet a different set of income requirements.
Genentech Oncology Access Solutions for TECENTRIQ can refer eligible patients to the Genentech Oncology Co-pay Program,* for help with the OOP cost associated with TECENTRIQ.
If eligible publicly or commercially insured patients have difficulty paying for their co-pay, co-insurance or other OOP costs, Genentech Oncology Access Solutions can refer them to an independent co-pay assistance foundation supporting their disease state.†
The Genentech Patient Foundation helps people affected by serious medical conditions get the TECENTRIQ they have been prescribed. People who do not have health insurance, who have health insurance that does not cover their TECENTRIQ, or who can't afford their OOP costs may get free medicine.‡
*This Genentech Oncology Co-pay Program is valid ONLY for patients with commercial insurance who have a valid prescription for a Food and Drug Administration (FDA)-approved indication of a Genentech medication. Patients using Medicare, Medicaid, or any other federal or state government program to pay for their medications are not eligible.
Under the Program, the patient will pay a co-pay. After reaching the maximum Program benefit, the patient will be responsible for all out-of-pocket costs.
All participants are responsible for reporting the receipt of all Program benefits as required by any insurer or by law. No party may seek reimbursement for all or any part of the benefit received through this Program. This Program is void where prohibited by law. Genentech reserves the right to rescind, revoke, or amend the Program without notice at any time. Additional eligibility criteria apply. See full terms and conditions at www.copayassistancenow.com.
†Genentech Oncology does not influence or control the operations or eligibility criteria of any independent co-pay assistance foundation and cannot guarantee co-pay assistance after a referral from Genentech Oncology Access Solutions. The foundations to which we refer patients are not exhaustive or indicative of Genentech Oncology's endorsement or financial support. There may be other foundations to support the patient’s disease state.
‡To be eligible for free Genentech medicine from the Genentech Patient Foundation, insured patients who have coverage for their medicine must have exhausted all other forms of patient assistance (including the Genentech Oncology Co-pay Program and support from independent co-pay assistance foundations) and must meet financial criteria. Uninsured patients and insured patients without coverage for their medicine must meet different financial criteria.
Genentech Oncology Access Solutions provides reliable, effective access and reimbursement support to assist your patients and practice after TECENTRIQ is prescribed.
Determine which patient assistance option is right for your patient with the Patient Assistance Tool.
To enroll in Genentech Oncology Access Solutions, complete and submit the:
Each program has its own time period in which your eligible patients will receive assistance. You can call us at (866) 422-2377 for more information.
To learn more about our programs and services:
TECENTRIQ Prescribing Information. Genentech, Inc.
TECENTRIQ Prescribing Information. Genentech, Inc.
Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Hepatobiliary Cancers V.1.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed March 29, 2022. To view the most recent and complete version of the guideline, go online to www.NCCN.org.
Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Hepatobiliary Cancers V.1.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed March 29, 2022. To view the most recent and complete version of the guideline, go online to www.NCCN.org.
Finn RS, Qin S, Ikeda M, et al; IMbrave150 Investigators. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894-1905.
Finn RS, Qin S, Ikeda M, et al; IMbrave150 Investigators. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894-1905.
Cheng A-L, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.
J Hepatol. 2022;76:862-873.
Cheng A-L, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.
J Hepatol. 2022;76:862-873.
Finn RS, Qin S, Ikeda M, et al. IMbrave150: updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC). Paper presented at: 2021 American Association for Cancer Research (AACR) Annual Meeting; April 10-15, 2021; virtual conference.
Finn RS, Qin S, Ikeda M, et al. IMbrave150: updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC). Paper presented at: 2021 American Association for Cancer Research (AACR) Annual Meeting; April 10-15, 2021; virtual conference.
Data on file. Clinical Study Report YO40245. Genentech, Inc.
Data on file. Clinical Study Report YO40245. Genentech, Inc.
Li D, Sedano S, Allen R, Gong J, Cho M, Sharma S. Current treatment landscape for advanced hepatocellular carcinoma: patient outcomes and the impact on quality of life. Cancers. 2019;11:841.
Li D, Sedano S, Allen R, Gong J, Cho M, Sharma S. Current treatment landscape for advanced hepatocellular carcinoma: patient outcomes and the impact on quality of life. Cancers. 2019;11:841.
Kudo M, Finn R, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 noninferiority trial. Lancet. 2018;391:1163-1173.
Kudo M, Finn R, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 noninferiority trial. Lancet. 2018;391:1163-1173.
Data on file. Study Protocol YO40245. Genentech, Inc.
Data on file. Study Protocol YO40245. Genentech, Inc.
Galle PR, Finn RS, Qin S, et al. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22:991-1001.
Galle PR, Finn RS, Qin S, et al. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22:991-1001.
Data on file. Roche.
Data on file. Roche.
Avastin (bevacizumab) Prescribing Information. Genentech, Inc.
Avastin (bevacizumab) Prescribing Information. Genentech, Inc.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.